Julian Harrison
Stock Analyst at BTIG
(2.13)
# 2,764
Out of 4,732 analysts
41
Total ratings
42.42%
Success rate
-3.29%
Average return
Main Sectors:
Stocks Rated by Julian Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AVTX Avalo Therapeutics | Initiates: Buy | $40 | $6.75 | +492.59% | 1 | Dec 19, 2024 | |
| RNAC Cartesian Therapeutics | Initiates: Buy | $42 | $19.29 | +117.73% | 1 | Dec 19, 2024 | |
| KROS Keros Therapeutics | Downgrades: Neutral | n/a | $10.86 | - | 3 | Dec 12, 2024 | |
| ANAB AnaptysBio | Downgrades: Neutral | n/a | $15.85 | - | 2 | Dec 2, 2024 | |
| OTLK Outlook Therapeutics | Maintains: Buy | $50 → $9 | $2.23 | +303.59% | 5 | Nov 29, 2024 | |
| ACRS Aclaris Therapeutics | Upgrades: Buy | $8 | $2.57 | +211.28% | 4 | Nov 19, 2024 | |
| VYNE VYNE Therapeutics | Initiates: Buy | $8 | $2.70 | +196.30% | 1 | Nov 18, 2024 | |
| VRDN Viridian Therapeutics | Maintains: Buy | $56 → $61 | $18.13 | +236.46% | 3 | Sep 26, 2024 | |
| RZLT Rezolute | Maintains: Buy | $13 → $15 | $4.87 | +208.01% | 2 | Sep 10, 2024 | |
| LQDA Liquidia | Maintains: Buy | $29 → $25 | $12.89 | +93.95% | 3 | Aug 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $41 → $51 | $36.82 | +38.51% | 2 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.58 | - | 4 | Jun 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $6.16 | +598.05% | 1 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $40 | $20.62 | +93.99% | 2 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $8.58 | +144.76% | 1 | Apr 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $37.06 | +16.03% | 1 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $4 | $2.07 | +93.24% | 1 | Nov 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $150 | $0.57 | +26,078.01% | 1 | Oct 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $43.81 | -17.83% | 1 | Mar 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $358.93 | - | 2 | Feb 11, 2022 |
Avalo Therapeutics
Dec 19, 2024
Initiates: Buy
Price Target: $40
Current: $6.75
Upside: +492.59%
Cartesian Therapeutics
Dec 19, 2024
Initiates: Buy
Price Target: $42
Current: $19.29
Upside: +117.73%
Keros Therapeutics
Dec 12, 2024
Downgrades: Neutral
Price Target: n/a
Current: $10.86
Upside: -
AnaptysBio
Dec 2, 2024
Downgrades: Neutral
Price Target: n/a
Current: $15.85
Upside: -
Outlook Therapeutics
Nov 29, 2024
Maintains: Buy
Price Target: $50 → $9
Current: $2.23
Upside: +303.59%
Aclaris Therapeutics
Nov 19, 2024
Upgrades: Buy
Price Target: $8
Current: $2.57
Upside: +211.28%
VYNE Therapeutics
Nov 18, 2024
Initiates: Buy
Price Target: $8
Current: $2.70
Upside: +196.30%
Viridian Therapeutics
Sep 26, 2024
Maintains: Buy
Price Target: $56 → $61
Current: $18.13
Upside: +236.46%
Rezolute
Sep 10, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $4.87
Upside: +208.01%
Liquidia
Aug 20, 2024
Maintains: Buy
Price Target: $29 → $25
Current: $12.89
Upside: +93.95%
Jul 24, 2024
Maintains: Buy
Price Target: $41 → $51
Current: $36.82
Upside: +38.51%
Jun 17, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.58
Upside: -
May 20, 2024
Initiates: Buy
Price Target: $43
Current: $6.16
Upside: +598.05%
May 10, 2024
Maintains: Buy
Price Target: $32 → $40
Current: $20.62
Upside: +93.99%
Apr 12, 2024
Initiates: Buy
Price Target: $21
Current: $8.58
Upside: +144.76%
Dec 20, 2023
Initiates: Buy
Price Target: $43
Current: $37.06
Upside: +16.03%
Nov 29, 2023
Assumes: Buy
Price Target: $4
Current: $2.07
Upside: +93.24%
Oct 11, 2023
Reinstates: Buy
Price Target: $150
Current: $0.57
Upside: +26,078.01%
Mar 9, 2023
Initiates: Buy
Price Target: $36
Current: $43.81
Upside: -17.83%
Feb 11, 2022
Initiates: Neutral
Price Target: n/a
Current: $358.93
Upside: -